Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zheng, Pan, Xiao-Fen, Wu, Fu-Qun, Ma, Li-Yuan, Liu, Da-Peng, Liu, Ying, Feng, Ting-Ting, Meng, Fan-Yi, Liu, Xiao-Li, Jiang, Qian-Li, Chen, Xiao-Qin, Liu, Jing-Lei, Liu, Ping, Chen, Zhu, Chen, Sai-Juan, Zhou, Guang-Biao
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://www.ncbi.nlm.nih.gov/pubmed/19606213
http://dx.doi.org/10.1371/journal.pone.0006257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://www.ncbi.nlm.nih.gov/pubmed/19606213
http://dx.doi.org/10.1371/journal.pone.0006257

Ejemplares similares